Name | bml-210 |
---|---|
Synonyms |
BML-210
N'-(2-aminophenyl)-N-phenyloctanediamide N-(2-Aminophenyl)-N'-phenyloctanediamide Octanediamide, N-(2-aminophenyl)-N-phenyl- |
Description | BML-210 is a novel HDAC inhibitor, and its mechanism of action has not been characterized.IC50 value: 5 μM[1]Target: HDAC4In vitro: Cell cycle analysis indicated that HeLa cell treatment with 20 and 30 μM concentration of BML-210 increased the proportion of cells in G0/G1 phase, and caused accumulation in subG1, indicating that the cells are undergoing apoptosis[2]. BML-210 inhibits the growth of NB4 cells in dose- and time-dependent manner[3].In vivo: |
---|---|
Related Catalog | |
Target |
HDAC4:MEF2 |
References |
Density | 1.2±0.1 g/cm3 |
---|---|
Boiling Point | 632.5±40.0 °C at 760 mmHg |
Molecular Formula | C20H25N3O2 |
Molecular Weight | 339.431 |
Flash Point | 336.3±27.3 °C |
Exact Mass | 339.194672 |
PSA | 84.22000 |
LogP | 2.58 |
Appearance | white solid |
Vapour Pressure | 0.0±1.9 mmHg at 25°C |
Index of Refraction | 1.633 |
Storage condition | -20℃ |
Hazard Statements | H413 |
---|---|
RIDADR | NONH for all modes of transport |